Un appel à répondre à la stigmatisation dans les environnements de soins de santé, en faisant participer les communautés marginalisées dans la prévention et en continuant de tester des modèles innovants. Pour en savoir plus, en Anglais, veuillez lire les informations ci-dessous.
Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.
By Clare Morgan
As new treatments for hepatitis C reshape the landscape, new data from UNSW underscore the need to address issues including discrimination, stigma and engaging marginalised communities.
Tens of thousands of Australians have been cured of Hepatitis C since new treatments were made universally available last year, and a report released last month said Australia is on track to eliminate hepatitis C by 2026.
But while new treatments continue to dramatically reshape the landscape, data from the Centre for Social Research in Health's (CSRH) Annual Report of Trends in Behaviour 2017: Viral Hepatitis in Australia underscores the need for caution.
Addressing stigma in healthcare settings, engaging marginalised communities in prevention, and continuing to trial innovative models of care will all be imperative if the 'new era' of treatment is to fulfil its promise, the report says.
It also notes the challenges of dealing with hepatitis B: about one third of people living with the disease are yet to be diagnosed and only 6% have been treated.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.
Thumbnail Flickr CC Sanofi Pasteur